Home › Trials › NCT05641142

Evaluating Antiplatelet and Anticoagulation Therapy in Hereditary Hemorrhagic Telangiectasia

Prospective Study of Antiplatelet and Anticoagulation Therapy in Hereditary Haemorrhagic Telangiectasia

Not applicable Interventional University Hospital, Clermont-Ferrand · NCT05641142

This study is testing how well people with Hereditary Hemorrhagic Telangiectasia can handle new blood-thinning treatments compared to not using them, to find out which ones work best for them.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment100 (estimated)
Ages18 Years and up
SexAll
SponsorUniversity Hospital, Clermont-Ferrand Academic / other
Locations18 sites (Angers and 17 other locations)
Trial IDNCT05641142 on ClinicalTrials.gov

What this trial studies

This clinical trial aims to assess the tolerance of anticoagulant and/or antiplatelet therapy in patients with Hereditary Hemorrhagic Telangiectasia (HHT) by comparing a new treatment exposure period to a reference non-exposure period. Participants will be monitored over two years, with evaluations including biological monitoring of ferritin and hemoglobin levels, as well as questionnaires assessing epistaxis severity and quality of life. The study seeks to identify which therapies are best tolerated in this patient population, where current treatment guidelines are lacking.

Who should consider this trial

Good fit: Ideal candidates for this study are adults over 18 years old diagnosed with Rendu-Osler disease who have recently started antiplatelet and/or anticoagulant therapy.

Not a fit: Patients who have not started treatment or have been on treatment for more than three months, as well as pregnant or breastfeeding women, may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide critical insights into effective management strategies for patients with Hereditary Hemorrhagic Telangiectasia, potentially improving their quality of life.

How similar studies have performed: While there is limited guidance on anticoagulant and antiplatelet therapy in Rendu-Osler disease, this study represents a novel approach to understanding treatment tolerance in this specific patient population.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Patient with Rendu-Osler disease with an indication of antiplatelet and/or anticoagulant introduced for less than 3 months (inclusion period within 3 months of exposure)
* Age \> 18 years old
* Patient able to understand and agree to participate in the study
* Affiliation to a social security system

Exclusion Criteria:

* Patient with an indication of antiplatelet and/or anticoagulant but for whom treatment has not been introduced or introduced for more than 3 months
* Refusal to participate
* Pregnant woman or who are breast feeding
* Patients under maintenance of justice, wardship or legal guardianship

Where this trial is running

Angers and 17 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Hereditary Hemorrhagic TelangiectasiaRendu Osler Diseaseepistaxishemorrhageanticoagulant therapyantiplatelet therapy
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.